1. Treatment Decisions in Chemorefractory Follicular Lymphoma

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Chemorefractory Follicular Lymphoma

5. Risk Stratification

6. Integration of Genetic Mutations Into Risk Stratification (M7-FLIPI)

7. Prognostic Value of Post-Treatment PET Scan

8. NCCN Recommended Treatments for Follicular Lymphoma (Grades 1-2)*

9. Phase 2 Trial of Idelalisib Monotherapy in Relapsed/Refractory FL

10. Comparison of PFS With Previous Line of Therapy Before Study Inclusion in Patients With Follicular Lymphoma

11. Phase 2 Idelalisib Monotherapy Adverse Events of Interest

12. Phase 2 Trial of Ibrutinib Monotherapy in Relapsed/Refractory FL

13. Lenalidomide Plus Rituximab in Relapsed FL Phase 3 CALGB 50401 Study

14. Phase 3b MAGNIFY Study Lenalidomide Plus Rituximab in Chemoresistant NHL

15. Obinutuzumab Plus Bendamustine Phase 3 GADOLIN Study

16. Radioimmunotherapy

17. CAR T-Cell Therapy

18. Personalizing Treatment in the Chemorefractory Population

19. Planned Intergroup S1608 Phase 2 Trial

20. Stem Cell Transplant in Patients With Early Chemoimmunotherapy Failure

21. Rational Treatment Combinations

22. Future Directions and Unmet Needs

23. Key Takeaways